These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12658064)

  • 21. Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
    Chung TL; Pumplin DW; Holton LH; Taylor JA; Rodriguez ED; Silverman RP
    Plast Reconstr Surg; 2007 Oct; 120(5):1281-1288. PubMed ID: 17898601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study.
    Kaul S; Makkar RR; Nakamura M; Litvack FI; Shah PK; Forrester JS; Hutsell TC; Eigler NL
    Circulation; 1996 Nov; 94(9):2228-34. PubMed ID: 8901676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
    Ahmad S; Jeske WP; Ma Q; Walenga JM; Fareed J
    Thromb Res; 2001 Apr; 102(2):143-51. PubMed ID: 11323025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.
    Makkar RR; Eigler NL; Kaul S; Frimerman A; Nakamura M; Shah PK; Forrester JS; Herbert JM; Litvack F
    Eur Heart J; 1998 Oct; 19(10):1538-46. PubMed ID: 9820993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Shen XL; Wang YL; Zang WJ; Wang B
    Br J Pharmacol; 2013 Jun; 169(4):848-59. PubMed ID: 23083032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
    Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
    J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T; Sugidachi A; Naganuma H; Asai F
    Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS; Driscoll EM; Lucchesi BR
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
    André P; Arbeille B; Drouet V; Hainaud P; Bal dit Sollier C; Caen JP; Drouet LO
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):56-63. PubMed ID: 8548427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.